Protox Therapeutics uses genetic engineering to transform naturally occurring proteins into novel targeted therapeutics for the treatment of prostate diseases and various cancers. Protox is advancing a pipeline of clinical-stage product candidates derived from its PORxin™ and INxin™ technology platforms. Protox’s lead drugs currently in clinical development include PRX302 for the treatment of benign prostatic hyperplasia (BPH, commonly known as enlarged prostate) and localized prostate cancer, as well as PRX321 for primary brain cancer (glioblastoma multiforme and astrocytoma).

Video - Click HereCLICK HERE:
BTV-Business Television features Protox Therapeutics: management interviews, product and service highlights and in-depth plans for company growth.


Email Update

To receive the latest information about
developments at Protox, sign up here
to be included on our email list.

NAME:         
EMAIL:  

What's New

June 29 2009
Protox to Present Benign Prostatic Hyperplasia Data at Canadian Urology Conference

June 16, 2009
Protox Appoints Dr. Alexander Giaquinto to Board of Directors

May 20, 2009
Protox completes $2.31 million private placement

May 15, 2009
Protox reports 2009 first quarter results

 

Events

PRX302 Phase 2 BPH Data Webcast
When: November 24, 5:00 p.m. ET
Webcast link

 

Stock Quote

LAST TRADE:$0.365
TRADE TIME:2:05PM EST
CHANGE:$0.00 (0.00%)
PREV CLOSE: $0.365
OPEN:$0.365
BID:$0.365
ASK:$0.395